MedTrace Logo

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

NCT07742332 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-08-03

No results posted yet for this study

Summary

The subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.

Conditions

  • EGFR
  • NSCLC (Non-small Cell Lung Cancer)
  • Locally Advanced Non-Small Cell Lung Cancer
  • Radiotherapy
  • Chemotherapy

Interventions

DRUG

Fumetinib combined platinum-based double chemotherapy

Fumetinib combined platinum-based double chemotherapy

COMBINATION_PRODUCT

Concurrent Radiochemotherapy

Concurrent Radiochemotherapy

Sponsors & Collaborators

  • Peng Zhang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-25
Primary Completion
2027-11-25
Completion
2032-11-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07742332 on ClinicalTrials.gov